Methylglyoxal Adducts Levels in Blood Measured on
early cancer detection
methylglyoxal adducts
near-infrared spectroscopy
point-of-care
secretome
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
18 Sep 2021
18 Sep 2021
Historique:
received:
11
08
2021
revised:
06
09
2021
accepted:
10
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
The altered glucose metabolism characterising cancer cells determines an increased amount of methylglyoxal in their secretome. Previous studies have demonstrated that the methylglyoxal, in turn, modifies the protonation state (PS) of soluble proteins contained in the secretomes of cultivated circulating tumour cells (CTCs). In this study, we describe a method to assess the content of methylglyoxal adducts (MAs) in the secretome by near-infrared (NIR) portable handheld spectroscopy and the extreme learning machine (ELM) algorithm. By measuring the vibration absorption functional groups containing hydrogen, such as C-H, O-H and N-H, NIR generates specific spectra. These spectra reflect alterations of the energy frequency of a sample bringing information about its MAs concentration levels. The algorithm deciphers the information encoded in the spectra and yields a quantitative estimate of the concentration of MAs in the sample. This procedure was used for the comparative analysis of different biological fluids extracted from patients suspected of having cancer (secretome, plasma, serum, interstitial fluid and whole blood) measured directly on the solute left on a surface upon a sample-drop cast and evaporation, without any sample pretreatment. Qualitative and quantitative regression models were built and tested to characterise the different levels of MAs by ELM. The final model we selected was able to automatically segregate tumour from non-tumour patients. The method is simple, rapid and repeatable; moreover, it can be integrated in portable electronic devices for point-of-care and remote testing of patients.
Identifiants
pubmed: 34578748
pii: nano11092432
doi: 10.3390/nano11092432
pmc: PMC8472697
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Transl Med. 2016 May 12;14(1):133
pubmed: 27176720
NPJ Precis Oncol. 2018 Nov 19;2:26
pubmed: 30480095
Nat Rev Clin Oncol. 2017 Jun;14(6):347-364
pubmed: 28094261
Int J Nanomedicine. 2020 Apr 01;15:2303-2314
pubmed: 32280222
Cancers (Basel). 2020 May 26;12(6):
pubmed: 32466587
Onco Targets Ther. 2020 Dec 22;13:13077-13085
pubmed: 33376356
Molecules. 2020 Oct 15;25(20):
pubmed: 33076318
Int J Mol Sci. 2021 Jan 26;22(3):
pubmed: 33530491
Cancer Res Treat. 2018 Jul;50(3):883-893
pubmed: 28934848
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819830411
pubmed: 30764728
Biosens Bioelectron. 2018 Feb 15;100:361-373
pubmed: 28946108
Micromachines (Basel). 2020 Jan 22;11(2):
pubmed: 31979030
Int J Mol Sci. 2020 Jul 01;21(13):
pubmed: 32630302
Anal Bioanal Chem. 2014 Jul;406(17):4013-31
pubmed: 24668067
Micromachines (Basel). 2018 Sep 20;9(10):
pubmed: 30424411
PLoS One. 2017 Jun 26;12(6):e0179644
pubmed: 28651006
Chem Soc Rev. 2014 Dec 21;43(24):8200-14
pubmed: 25156745
J Am Soc Mass Spectrom. 2018 May;29(5):817-826
pubmed: 28889248